The Role of Sphingolipids and Specialized Pro-Resolving Mediators in Alzheimer’s Disease

Nienke M. de Wit, Kevin Mol, Sabela Rodríguez-Lorenzo, Helga E. de Vries, Gijs Kooij*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Alzheimer’s disease (AD) is the leading cause of dementia worldwide giving rise to devastating forms of cognitive decline, which impacts patients’ lives and that of their proxies. Pathologically, AD is characterized by extracellular amyloid deposition, neurofibrillary tangles and chronic neuroinflammation. To date, there is no cure that prevents progression of AD. In this review, we elaborate on how bioactive lipids, including sphingolipids (SL) and specialized pro-resolving lipid mediators (SPM), affect ongoing neuroinflammatory processes during AD and how we may exploit them for the development of new biomarker panels and/or therapies. In particular, we here describe how SPM and SL metabolism, ranging from ω-3/6 polyunsaturated fatty acids and their metabolites to ceramides and sphingosine-1-phosphate, initiates pro- and anti-inflammatory signaling cascades in the central nervous system (CNS) and what changes occur therein during AD pathology. Finally, we discuss novel therapeutic approaches to resolve chronic neuroinflammation in AD by modulating the SPM and SL pathways.

Original languageEnglish
Article number620348
JournalFrontiers in Immunology
Volume11
DOIs
Publication statusPublished - 29 Jan 2021

Cite this